PROSPECTS OF THE USE "STIMFORTE" IN CHRONIC HEPATITIS B


Cite item

Full Text

Abstract

Despite the fact that over the last few years downward trend in the incidence of acute forms of viral hepatitis B continues, the incidence of chronic hepatitis B (CHV) has increased by 2.5 times since 1998. To date, there are a sufficient number of antiviral drugs, but their use is associated with a set of contraindications, as well as the development of resistance. In this study there was performed an evaluation of a new national drug " Stimforte " in patients with chronic viral hepatitis B (CVHB - DNA positive, HBsAg - positive) at the stage of exacerbation. In the study there were included 28 patients with chronic hepatitis B (HBsAg positive), at different grades of activity, at a stage of viral replication. The diagnosis of chronic hepatitis B was made on the presence in a history acute viral hepatitis for more than 1 year, complaints, hepatolienal, astenovegetative, cytolytic syndromes, the presence of DNA-HBV, anti-HBcore IgM, HBsAg. After 1 course of treatment with " Stimforte " the well-being of patients has improved: in 30% of patients asthenic- vegetative syndrome had disappeared, weakness, fatigue and dyspeptic symptoms were decreased. The use of "Stimforte" in chronic hepatitis B with positive HBsAg at the stage of exacerbation contributed to a more rapid normalization of such indices as ALT, AST, compared with those in the control group. Long-term biochemical and virological remission was achieved in 40 %. It is established that during the treatment the viral load was reduced progressively until the undetectable or low level of HBV DNA and anti-HBc IgM disappeared. In only one case an allergic reaction was observed, which has not hindered to perform a complete course of treatment. No other side effects were detected. The inclusion of the drug "Stimforte" in the complex therapy of patients with exacerbation of chronic hepatitis B reduces the time of recovery of immune status and functional activity of IFN system and contributes to reduction of the viral load or elimination of the virus.

About the authors

L. V Pogorelskaya

Russian Medical Academy of Postgraduate Education

Email: lv2009p@mail.ru
доктор мед. наук, проф. каф. инфекционных болезней 2/1 Barrikadnaya Str., Moscow, Russian Federation, 123995

I. N Khlopova

D. I. Ivanovsky Institute of Virology

канд. мед. наук 16, Gamalei Str., Moscow, Russian Federation; 123098

S. S Grigoryan

N.F.Gamaleya Research Institute of Epidemiology and Microbiology

проф. доктор мед. наук 18, Gamalei Str., Moscow, Russian Federation, 123098

I. P Tryakina

Russian Medical Academy of Postgraduate Education

канд. мед. наук, доцент каф. инфекционных болезней 2/1 Barrikadnaya Str., Moscow, Russian Federation, 123995

N. A Rick

Russian Medical Academy of Postgraduate Education

ординатор каф. инфекционных болезней 2/1 Barrikadnaya Str., Moscow, Russian Federation, 123995

D. G Maldov

«SKY LTD»

канд. биол. наук 113/1, E-523, Leninsky Avenue, Moscow, Russian Federation, 117198

References

  1. Fan H.L., Yang P.S., Chen H.W. et al. Predictors of the outcomes of acute-on-chronic hepatitis B liver failure. World J. Gastroenterol. 2012; 18(36): 5078-83.
  2. Погорельская Л.В., Никитина Г.Ю., Алешкович Т.В., Чемерис О.Ю. Применение стимфорте при хроническом гепатите В. Актуальные вопросы организации лечебно-диагностического процесса в многопрофильной клинической больнице. В кн.: Тезисы докладов на научно-практической конференции, посвященной 100-летию Государственной клинической больницы имени С.П. Боткина. 1910-2010. М.; 2010: 218-9.
  3. Ильичев А.В., Бельков А.П., Мальдов Д.Г., Асташкин Е.И. Секреция гранул нейтрофилов человека под действием формил пептида и препарата «Стимфорте». Иммунология. 2009; 3: 159-61.
  4. Мальдов Д.Г., Бельков А.П., Ильичев А.В., Асташкин Е.И. Влияние комплексного гидрофильного низкомолекулярного препарата «Стимфорте» на функциональную активность фагоцитов крови человека. Иммунология. 2009; 2: 95-7.
  5. Хоперская О.А. (RU), Мальдов Д.Г. (RU), Асташкин Е.И. (RU). Патент № 008646. Реестр евразийских патентов. Евразийское патентное ведомство; 2007: 10.
  6. Российский статистический ежегодник. Заболеваемость населения по основным классам болезней. М.: 2012. Федеральная служба государственной статистики.

Copyright (c) 2013 Eco-vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies